男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Vaccine from BioNTech, Fosun to enter phase 2 trials

By SHI JING in Shanghai | chinadaily.com.cn | Updated: 2020-11-26 15:42
Share
Share - WeChat

German biotechnology company BioNTech SE and Shanghai Fosun Pharmaceutical (Group) Co Ltd jointly announced on Wednesday that their lead mRND COVID-19 vaccine candidate BNT162b2 will be evaluated in a phase 2 clinical trial.

The phase 2 clinical trial will be carried out in Taizhou and Lianshui of East China's Jiangsu province. Jiangsu Provincial Center for Disease and Prevention will be responsible for the trial.

The online recruitment of volunteers will commence with the recruitment of 960 healthy participants, aged between 18 and 85, to assess the safety and immunogenicity of the vaccine candidate and to support future biologic license applications in China.

In the ongoing phase 3 clinical study of the vaccine, BNT162b2 met all primary efficacy endpoints, with an efficacy rate of 95 percent in preventing symptomatic COVID-19 infections. Sufficient safety data was collected to support the submission of an emergency use authorization to the US Food and Drug Administration on Nov 20. In addition, BNT162b2 is currently under regulatory review by regulatory authorities in Europe, the United Kingdom and Canada.

According to Ugur Sahin, CEO and co-founder of BioNTech, the clinical trial research carried out in China is an important part of the global research and development of the company's COVID-19 vaccine and marks an important step in bringing this vaccine to the people of China.

On March 13, Fosun Pharma became the strategic partner of BioNTech in China, jointly developing and commercializing vaccine products for COVID-19 based on its proprietary mRNA technology platform in China. Apart from discussing the research and development plans with partners and completing clinical trials in China, Fosun Pharma has also designed and completed animal challenge trials of selected mRNA vaccines, including BNT162b2, in collaboration with Chinese research institutes, and shared outcomes with partners in a timely manner.

Hui Aimin, chief medical officer of Fosun Pharma, said that the COVID-19 pandemic proves once again that global cooperation is needed to control infectious diseases.

"As an important part of global research and development, the phase two clinical study with BNT162b2 in China will not only provide key data for the launch of the vaccine in China, but also may play a positive role in the widespread promotion and use of the vaccine throughout Asia and around the world," he said.

Fosun Pharma announced on Wednesday a private placement plan in the A-share market. The financing value is estimated at around 4.98 billion yuan ($758.25 million), which will be mainly used for the development, commercial license and introduction permits of innovative drugs, including the development of the highly anticipated mRNA COVID-19 vaccine.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 濮阳县| 彭山县| 武功县| 香河县| 乌苏市| 资阳市| 荣成市| 旬邑县| 石狮市| 任丘市| 黄大仙区| 龙岩市| 梁河县| 永年县| 虹口区| 奉新县| 宜城市| 游戏| 紫阳县| 儋州市| 绥阳县| 惠安县| 大化| 应城市| 漳浦县| 桂林市| 孝义市| 巴林右旗| 龙岩市| 米脂县| 万全县| 布尔津县| 锦屏县| 北碚区| 句容市| 北流市| 宁晋县| 平安县| 万全县| 苍山县| 资兴市|